Alkermes opened higher at $45.67, compared with its previous close of $45.37. In the last trading session, the stock traded between $44.78 and $46.35. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Alkermes is now worth
$ 149.27
giving a profit of
$ 49.27 (49.27%)
Note: Past profits do not guarantee future returns.
Rating from 11 Analysts
Today's Change
$-0.16 (-0.34%)
Day High
$46.35
Day Low
$44.78
Day Open
$45.67
Prev Close
$45.37
Volume
4,07,826
1W Return
2.37%
1M Return
10.79%
3M Return
-6.42%
6M Return
34.13%
1Y Return
43.77%
Market Cap ($ Mn)
7,585
PE Ratio
124.76
PB Ratio
4.39
PEG Ratio
1.02
ROE
14.82%
ROCE
14.73%
EPS (TTM)
$0.00
1 Week
2.37%
1 Month
10.79%
3 Months
-6.42%
6 Months
34.13%
9 Months
29.63%
Alkermes reports positive phase 1b data for ADHD drug ALKS 7290
Alkermes reports positive phase 1b data for ALKS 7290, an orexin 2 receptor agonist for ADHD. The drug showed dose-dependent reductions in AISRS scores (14.0 for 20mg, 19.0 for 50mg). No serious treatment-emergent adverse events were reported in the 50-adult cohort. A phase 2 study involving 312 participants is currently enrolling.
1mo agoAlkermes appoints Anne Whitaker as independent director
Alkermes appoints Anne C. Whitaker as independent director. Whitaker previously served as CEO at Aerami Therapeutics and Novoclem. She currently sits on boards of Basilea Pharmaceutica and ICON plc. Appointment aims to support neuroscience pipeline execution.
1mo agoAlkermes alixorexton phase 2 data published in The Lancet Neurology
Alkermes published Vibrance-1 phase 2 data for alixorexton in The Lancet Neurology. All doses (4 mg, 6 mg, 8 mg) normalized wakefulness metrics in 92 NT1 patients. 6 mg dose significantly reduced weekly cataplexy rate versus placebo. Drug was well tolerated with no serious adverse events reported. Global phase 3 Brilliance program now underway for NT1 and NT2.
2mo agoAlkermes affirms FY26 sales guidance of $1.730B-$1.840B
Alkermes reaffirms its FY26 sales guidance of $1.730 billion to $1.840 billion, matching prior estimates and sitting near the $1.812 billion market consensus. This stability suggests consistent operational execution and managed expectations for the fiscal year.
3mo agoStifel reiterates Buy on Alkermes, raises target to $63
Stifel analyst Paul Matteis reiterated a Buy rating on Alkermes and raised the price target from $45 to $63, reflecting a positive valuation outlook. This follows a similar move by Needham, which maintained a Buy rating with a $62 target, while JP Morgan reinstated a Neutral rating with a $60 target.
3mo agoAlkermes to report second quarter results on July 28, 2026
Alkermes plc will announce its Q2 financial results on July 28, 2026, via a conference call and webcast. The company will discuss its performance in neuroscience-focused treatments, including commercial products and pipeline candidates. Investors can access the presentation and replay on its website.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,373.70 | +6.63% | $12,93,142.11M | 39.43 | |
| $275.20 | +1.53% | $6,62,491.71M | 31.06 | |
| $290.79 | +1.68% | $5,13,859.95M | 72.17 | |
| $146.33 | +3.83% | $3,61,021.28M | 117.74 | |
| $161.10 | +3.22% | $3,27,809.50M | 23.23 | |
| $174.40 | +2.88% | $2,70,478.36M | 24.32 | |
| $460.73 | +1.97% | $2,49,085.38M | 26.86 | |
| $165.61 | +4.03% | $2,05,348.95M | - | |
| $29.95 | +1.70% | $1,70,705.24M | 36.79 | |
| $39.14 | +2.22% | $1,32,689.61M | 11.15 | |
| $61.39 | +1.35% | $1,25,402.27M | 14.67 | |
| $48.68 | -0.12% | $1,05,059.03M | 16.01 |
An investment of $100 made 5 years ago in Alkermes is now worth
$ 149.27
giving a profit of
$ 49.27 (49.27%)
Note: Past profits do not guarantee future returns.
